摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Aethyl-dimethyl-phenyl-ammonium | 45847-05-0

中文名称
——
中文别名
——
英文名称
Aethyl-dimethyl-phenyl-ammonium
英文别名
Dimethyl-aethyl-phenyl-ammonium;Ethyldimethylanilinium;Phenylethyldimethylammonium;N-Aethyl-N,N-dimethyl-anilinium;Ethyl-dimethyl-phenyl-ammonium;N-Ethyl-N,N-dimethylanilinium;Ethyl-dimethyl-phenylazanium
Aethyl-dimethyl-phenyl-ammonium化学式
CAS
45847-05-0
化学式
C10H16N
mdl
——
分子量
150.244
InChiKey
OZBUYAXBRBBLTB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

文献信息

  • Non-aqueous absorbent and use thereof
    申请人:Sumiya Takashi
    公开号:US20050136247A1
    公开(公告)日:2005-06-23
    A non-aqueous absorbent comprising a crosslinked polymer which contains a structural unit having a carboxyl group and/or a sulfonate group in an amount of 20 to 100% weight in its molecule and in which from 30 to 100% by mol of the protons in the carboxyl group and/or the sulfonate group have been substituted by onium cations; a non-aqueous gel made of this non-aqueous absorbent and an organic solvent; and a non-aqueous absorbent sheet and a non-aqueous absorbent agent containing the non-aqueous absorbent. Because of having excellent capabilities of absorbing and holding various organic solvents such as alcohols and gelating, these materials are usable for various purposes, for example, lithium batteries, alcohol-based bactericidal materials or alcohol-based bactericides, cold insulating materials or cold insulators, gel sheets for cooling, fuel compositions for solid fuels or solid fuels using the same, fragrance materials or fragrances, patch materials or patches, insecticidal compositions or insecticides, fuel stores for fuel batteries or fuel batteries using the same.
    一种非吸收剂,包含交联聚合物,其分子中含有具有羧基和/或磺酸基的结构单元,其含量为20至100%重量,并且其中羧基和/或磺酸基中的30至100%摩尔的质子已被离子上离子替代物取代;由此制成的非凝胶和有机溶剂;以及含有非吸收剂的非吸收剂片和非吸收剂剂。由于具有吸收和保持各种有机溶剂(如醇类)的能力,以及凝胶化,这些材料可用于各种用途,例如电池,醇基杀菌材料或醇基杀菌剂,冷绝缘材料或冷绝缘材料,用于冷却的凝胶片,用于固体燃料的燃料组合物或使用相同的固体燃料,香料材料或香料,贴片材料或贴片,杀虫组合物或杀虫剂,燃料电池的燃料存储器或使用相同的燃料电池。
  • AFFINITY CONTROL OF TAGGING NOISE
    申请人:Giese Roger W.
    公开号:US20100255607A1
    公开(公告)日:2010-10-07
    Analytical methodology is disclosed in which a trace analyte in a sample is tagged to increase its signal strength for measurement, and an affinity substance is used at least after the tagging step (late in the method) to separate the tagged analyte from tagging noise, wherein the affinity substance is directed at the reactive part of the tag, at the reagent-reacted part of the tag, or at a nonreactive part of the analyte. This method includes the case where exposure of the sample to the affinity substance begins prior to and continues after the tagging reaction. The affinity substance comprises an affinity reagent such as an immobilized anti-body (immuno-affinity chromatography). This late use of an affinity substance (after the tagging reaction) is particularly important for methods in which trace analytes are reacted with a charge tag (tag possessing a charge) prior to detection by mass spectrometry.
    本文揭示了一种分析方法,其中样品中的微量分析物被标记以增加其测量信号强度,并且在标记步骤之后(在方法的后期)至少使用亲和物质来将标记的分析物与标记噪声分离,其中亲和物质定向于标记的反应部分,标记反应部分或分析物的非反应部分。该方法包括在样品暴露于亲和物质之前开始并在标记反应之后继续的情况。亲和物质包括亲和试剂,例如固定的抗体(免疫亲和色谱)。这种在标记反应之后使用亲和物质(晚期使用)对于在质谱检测之前用电荷标记(具有电荷的标记)反应微量分析物的方法尤其重要。
  • QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS
    申请人:Husfeld Craig
    公开号:US20120232053A1
    公开(公告)日:2012-09-13
    The invention provides compounds of the formula: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R 1-6 , a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
    该发明提供了以下式子的化合物:以盐或离子配对形式或其药学上可接受的盐形式存在,其中R1-6,a,Z和Q如规范中所定义。这些化合物是肌肉型受体拮抗剂。该发明还提供了含有这些化合物的制药组合物,制备这些化合物的过程以及使用这些化合物的方法,例如治疗慢性阻塞性肺疾病和哮喘等肺部疾病。
  • 1-Methyl-1h-imidazole-5-carboxylic acid derivatives
    申请人:JANSSEN PHARMACEUTICA N.V.
    公开号:EP0273531A1
    公开(公告)日:1988-07-06
    Novel 1-methyl-1H-imidazole-5-carboxylic acid derivatives of formula R1 is hydrogen or mercapto; R2 is hydrogen, C1-C7alkyl, C3-C7alkenyl, C3-C7alkynyl, C3-C7cycloalkyl, C5-C7cycloalkenyl; said C1-C7alkyl, C3-C7alkenyl, C3-C7alkynyl, C3-C7cycloalkyl, C5-C7cycloalkenyl being optionally substituted; R3 is C4-C13alkyl, C3-C7cycloalkyl, or C5-C7cycloalkenyl each unsubstituted or substituted; L is cyano, -COOR4, or a group -C( = G)-D-R6; a salt or stereoisomeric form thereof, which compounds are herbicidals; compositions containing such compounds as active ingredient and methods of preparing said compounds and compositions.
    式中的新型 1-甲基-1H-咪唑-5-羧酸生物 R1 是氢或巯基; R2 是氢、C1-C7烷基、C3-C7烯基、C3-C7炔基、C3-C7环烷基、C5-C7环烯基;所述C1-C7烷基、C3-C7烯基、C3-C7炔基、C3-C7环烷基、C5-C7环烯基被任选取代; R3 是各自未被取代或取代的 C4-C13 烷基、C3-C7 环烷基或 C5-C7 环烯基; L 是基、-COOR4、 或基团-C( = G)-D-R6; 其盐或立体异构体形式,这些化合物为除草剂;含有此类化合物作为活性成分的组合物以及制备所述化合物和组合物的方法。
  • Tricyclic 1H-imidazole-5-carboxylic acid derivatives
    申请人:JANSSEN PHARMACEUTICA N.V.
    公开号:EP0275603A1
    公开(公告)日:1988-07-27
    Novel tricyclic 1H-imidazole-5-carboxylic acid derivatives of formula wherein X is a radical of formula A is a C₁-C₅alkanediyl or a C₅-C₇cycloalkanediyl radical; and Y is O, S(O)m, NR⁹ or CH₂; the salts and stereochemically isomeric forms thereof, which compounds are herbicides; herbicidal compositions containing such compounds as active ingredient and methods of preparing said compounds.
    新颖的式三环 1H-咪唑-5-羧酸生物 其中 X 是式 A 的基 C₁-C₅ 烷二基或 C₅-C₇ 环烷二基;Y 是 O、S(O)m、NR⁹ 或 CH₂;其盐和立体化学异构体形式,这些化合物是除草剂;含有这些化合物作为活性成分的除草组合物以及制备所述化合物的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫